Fusion Antibodies Share Discussion Threads

[tidy 2] 18/9/2020 10:18

hTTps://twitter.com/andy47640/status/1306884790520606729?s=21

[acuere] 18/9/2020 10:14

No time to check but is this related to the Eli Lilly announcement this week?

[superg1] 18/9/2020 10:12

Nice to see.

The covid sleeper they all missed with most likely the best answer of the lot, neutralising antibodies to treat patents.

The antigen side in that news looks lucrative.

FAB already supply various antibodies to 8 of the top 10 (by revenue) Pharma companies.

[tomboyb] 18/9/2020 10:10

Dr Richard Buick, CTO of Fusion Antibodies, said: "We are committed to developing the highest quality reagents to be used in the fight against COVID-19. Recent lab studies have shown that results using our antigens correlate 100% with clinical data from patients infected with SARS-CoV-2. We are using these high quality antigens to pan our human antibody library for SARS-CoV-2 neutralising antibodies, and we are delighted to now be able to make these antigens available to companies and researchers around the world to Test, Track & Trace this disease."

Paul Kerr, CEO of Fusion Antibodies said: "According to the FDA, antigen tests will play a critical role in the fight against COVID-19 and like many other companies within the antibody world at large, we are leveraging our antigen expertise to create multiple antigens to be used against the COVID-19 pandemic. "

[tomboyb] 18/9/2020 10:08

8/09/2020 9:31am
UK Regulatory (RNS & others)

Fusion Antibodies (LSE:FAB)
Intraday Stock Chart

Friday 18 September 2020

Click Here for more Fusion Antibodies Charts.
TIDMFAB

RNS Number : 4285Z

Fusion Antibodies PLC

18 September 2020

Fusion Antibodies plc

("Fusion" or the "Company")

Update on R&D programme

Progress with coronavirus antigen and Library

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update on the Company's research and development programme.

The Company's proof-of-concept work on the Mammalian Antibody Library Discovery Platform (the "Library") continues to progress according to plan. The Company has made progress on the design, expression and validation of SARS-CoV-2 proteins, commonly known as Coronavirus spike proteins. These antigens have been tested by external partners against patient blood samples and show a 100% correlation with results from a leading certified benchmark test.

The Company's extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests. The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.

The Company has commenced use of these antigens to interrogate the Library for SARS-CoV-2 neutralising antibodies with a view to providing these as potential prophylactic and therapeutic candidates.

Dr Richard Buick, CTO of Fusion Antibodies, said: "We are committed to developing the highest quality reagents to be used in the fight against COVID-19. Recent lab studies have shown that results using our antigens correlate 100% with clinical data from patients infected with SARS-CoV-2. We are using these high quality antigens to pan our human antibody library for SARS-CoV-2 neutralising antibodies, and we are delighted to now be able to make these antigens available to companies and researchers around the world to Test, Track & Trace this disease."

Paul Kerr, CEO of Fusion Antibodies said: "According to the FDA, antigen tests will play a critical role in the fight against COVID-19 and like many other companies within the antibody world at large, we are leveraging our antigen expertise to create multiple antigens to be used against the COVID-19 pandemic. "

Enquiries:

[tidy 2] 18/9/2020 10:08

Game changer news for Both FAB and covid. The Company's extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests. The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.The Company has commenced use of these antigens to interrogate the Library for SARS-CoV-2 neutralising antibodies with a view to providing these as potential prophylactic and therapeutic candidates.

[tomboyb] 18/9/2020 10:06

2 quid plus -

[timbo003] 18/9/2020 09:50

Indeed, positive progress

At the very least, it provides an excellent showcase for the Mammalian Antibody Library Discovery Platform

[acuere] 18/9/2020 09:44

Excellent RNS.

This could get really exciting now.

[timbo003] 17/9/2020 11:29

>>>GWR

I doubt if they are involved with Lilly on this, but they wouldn't be able to tell us even if they were.

[gwr7] 17/9/2020 10:46

FAB aren't working with Lilly on that drug trial. The Telegraph has reported good preliminary results but as yet there is no statistical significance so could be due to chance. Integrity has flown out of the window with health companies. They realise covid is an opportunity to ramp themselves on twitter. We had the same last week with the greasy bloke at BBI.

[timbo003] 17/9/2020 10:24

Now if FAB were working with Lilly and were to provide them with a vital step for the efficient synthesis and scale up an antibody treatment against COVID-19 and negotiate a 1% royalty on future sales, then that would be more exciting. However, one of the major difficulties is to get a (cash rich) big pharma like Lilly to give away 1% of future sales, they would just rather pay a bit more for fee for service (and who can blame them)

[timbo003] 17/9/2020 09:47

I assume this morning's rise is due to the twitter rampers pumping away on FAB's retweet ( ) of this story in today's telegraph (about an hour ago), so a short lived rise I suspect:

[cumnor] 17/9/2020 09:25

Probably something to do with this yesterday-but FAB not involved I think. Still shows the importance of antibody research.

[money4me] 17/9/2020 09:19

Not a clue but I like it

[paraguay] 17/9/2020 09:16

looks like some upward movement yesterday and today. Any ideas why - or is it just talk of all this testing?

[superg1] 04/9/2020 10:35

On the Sp moves

There are only something like 26 mill shares with about 70 mill of those taken up by major holders.

The MMs carry no stock so simply react to buy sells and hence smalls buys and sells can cause big moves.

Certainly a very interesting company to research and understand before potential market interest.

Many will think BIO = Big fund raises and big spends. It's no the case at FAB they avoided that route early on and have chosen their path which adds the value but doesn't carry the risk.

[superg1] 04/9/2020 10:32

I really like the look of this company.

Initially through the Covid alarm but building an understanding then it does look like a good solid revenue generating company in a sector that is going to see a lot of interest, and accelerated due to the Covid pandemic.

Clearly they have been building the foundations and tech to match for the future as per recent news.

It's pretty much hidden from view on the Aim where the team look best suited to their business skills rather than PR ability in interviews, which helps then remain hidden, along with very few actually having a decent look at their business.

In short.

Developing antibodies for various end users to use in drugs trials. They are a service provider which include 8 of the top 10 pharmas by value as customers

So growing revenue from that but hidden potential revenue in the carries of drugs trails some in phase 2 going by what the CEO said. What trails and where I don't know yet.

The recent raise was to pursue Covid antibodies themselves to showcase their tech and obviously potentially create some material revenue from that, via the big names they are already linked with.


On the Covid side as the CEO out it, the aim would be to create Covid antibodies which can be administered to patients to neutralise Covid.

The whole problem with Covid, as with other viruses, is the time it takes the body to react and create its own antibodies. Meanwhile the virus multiplies at crazy rates unopposed, which create the complications that are causing many to die.

Basically a shot in the arm to neutralise covid before it gets to that point, loading the body with the correct antibodies to neutralise it before it can take hold.

Such a treatment would be massive for any serious virus like Covid.

[cumnor] 25/8/2020 10:12

AZN RNS on P1 trial of MAB from Covid plasma-not sure why they bothered as this so early phase and unlikely to suceed-but probably added a few hundred to their mrkt cap.
FAB does 'nothing' but MABs and hopefully they find a few (doing something on a potential covid one I believe) with real promise. Need to get their PR guys earning their salaries.

[timbo003] 19/8/2020 10:37

Indeed cumnor

On the subject of Royalties/Milestone payments, here is the relevant slide from their ShareSoc Presentation last November:

[cumnor] 19/8/2020 09:42

Boring, but solid, a bit like my GAN and BVC were for the last few years but happily always worth being patient with companies like these which can increase several fold in a short space of time. I like Fab's business model esp, as Timbo says, they may get a royalty on any MAB that big Pharma turns into something and they are working on developing several, so prospects are reasonably good, esp with attention turning more to MABS not just for cancers, autoimmune disease but now also managing complications of infection and pandemics. Also looks like they have enough cash to see them through next couple of years at present run rate. I suspect they will be taken out, or have several successes by then. The impatient will lose money here....

[timbo003] 19/8/2020 07:53

If they are getting listed as inventors they must be providing unique input and insights, so they should be in a position to insist that they not only get a fee for service, but also a significant share in any future revenues derived from their endeavours.

I do wonder whether in the past they have been too willing to just roll over and accept a fee for service without a share in the potential upside should the projects be successful.

[timbo003] 19/8/2020 07:40

Results seem okay, but I was hoping for a bit more detail on carried interest (Milestone payments and future royalties) in the new projects they are undertaking as this is where the treasure is buried IMO.

Here is the relevant bit from today's statement:

[money4me] 19/8/2020 07:38

All looks steady